stockrow
Friday 6 November 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
25.55
1.45
−5.37%
Follow ARQT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
116.33 | 119.18 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.81 | 7.38 | 7.33 | 9.82 | |
P/FCF ratio |
77.45 | 142.16 | 269.53 | 0.00 | |
P/Operating CF |
183.23 | 270.77 | 1,361.25 | 141.11 | |
P/B ratio |
14.19 | 15.52 | 16.07 | 19.50 | |
Price to Tangible BV |
15.00 | 16.54 | 17.38 | 21.15 | |
EV/Sales |
6.51 | 7.10 | 7.06 | 9.53 | |
EV/EBITDA |
89.88 | 92.59 | 724.90 | 0.00 | |
EV/Operating CF |
55.24 | 83.76 | 108.65 | (636.90) | |
EV/FCF |
74.09 | 136.76 | 259.37 | (168.11) | |
Quick Ratio |
2.50 | 2.46 | 2.26 | 2.83 | |
Current Ratio |
2.92 | 2.92 | 2.68 | 3.17 | |
Net Debt/EBITDA |
(15.30) | (7.75) | 13.19 | (5.92) | |
Debt/Assets |
20.86% | 22.29% | 23.79% | 25.17% | |
Debt/Equity |
0.45 | 0.49 | 0.58 | 0.58 | |
Asset Turnover |
1.14 | 1.10 | 1.03 | 0.96 | |
Operating CF/Net income |
2.15 | 0.84 | (0.20) | 1.51 | |
Capex/Depreciation |
(0.25) | (0.46) | 0.00 | 0.00 | |
Interest Coverage |
3.19 | 4.82 | (2.08) | 6.13 | |
Research and Development Expense of Revenue |
15.58% | 15.67% | 29.06% | 15.79% | |
Selling, General and Administrative Expense of Revenue |
69.21% | 63.25% | 70.28% | 60.98% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
8.59% | 9.83% | 10.14% | 7.77% | |
Graham Net Nets |
0.06 | 0.06 | 0.06 | 0.05 | |
Graham Number |
3.09 | 2.89 | 0.00 | 0.00 | |
Earnings Yield |
0.86% | 0.84% | (0.08%) | (0.45%) | |
Free Cash Flow Yield |
1.29% | 0.70% | 0.37% | (0.58%) | |
Revenue per Share |
1.10 | 0.99 | 0.81 | 1.02 | |
Operating CF per Share |
0.14 | 0.10 | 0.02 | 0.21 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.14 | 0.10 | 0.02 | 0.21 | |
Cash per Share |
1.98 | 1.83 | 1.73 | 1.74 | |
Shareholders Equity per Share |
1.86 | 1.69 | 1.47 | 1.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.86 | 1.69 | 1.47 | 1.49 | |
Free Cash Flow |
18.80 | 12.48 | 2.24 | 26.19 | |
Working Capital |
331.33 | 307.33 | 274.85 | 281.39 | |
Capital Expenditures |
(0.10) | (0.16) | — | 0.00 | |
Net Current Asset Value |
223.23 | 199.71 | 167.70 | 167.74 | |
EV/EBIT |
94.20 | 96.12 | 912.84 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
98.47 | 99.91 | 948.60 | 0.00 | |
| Other line items | |||||
Average Receivables |
143.20 | 130.93 | 114.90 | 109.65 | |
Average Payables |
7.07 | 10.84 | 21.41 | 13.37 | |
Average Inventory |
34.04 | 27.60 | 27.00 | 18.58 | |
Average Assets |
447.70 | 420.49 | 402.05 | 390.93 | |
Average Common Equity |
201.02 | 179.78 | 166.15 | 173.51 |
Columns are period end dates · fundamentals updated 6 Nov 2026